Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00412321 · ClinicalTrials.gov registry record · Phase 1

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

A Phase 1 study, sponsored by Centocor.

Completed
Registry status
Phase 1
Development phase
67
Enrollment target

NCT00412321: Completed Phase 1 study, sponsored by Centocor.

NCT00412321 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00412321, a Phase 1 study, has completed, sponsored by Centocor.

COMPLETED
Registry status
Phase 1
Development phase
67 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.

Primary Outcome

Number of Patients with adverse events will be reported.

Interventions

  • DRUG CNTO 328

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2005-05
Est. Completion 2011-04
Phase Phase 1
Centocor

33 total trials

What the finished NCT00412321 record still lists

NCT00412321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).

The record links to 0 conditions, and to 1 intervention - of which CNTO 328 is the first listed.

NCT00412321 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00412321 about?

NCT00412321 is a clinical study titled "A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease". The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.

What is the current status of trial NCT00412321?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2005-05. Estimated completion is 2011-04.

What interventions are being tested in trial NCT00412321?

The interventions under investigation include: CNTO 328 (DRUG).

Who is sponsoring clinical trial NCT00412321?

This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00412321's enrollment target sits among peer trials

67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00412321, the US trial registry maintained by the National Library of Medicine. NCT00412321 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.